JANUARY 18, 2024
The clinical evaluation, which will begin in February
2024 and run for a total period of 15 months, will
primarily assess the usability of Oleena® by measuring key indicators such as patient satisfaction and engagement, as well as clinical outcomes including symptom burden, anti-cancer treatment adherence and quality of life.
You can read the press release below to learn more.
